Work

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance

Year: 2020

Type: article

Source: JAIDS Journal of Acquired Immune Deficiency Syndromes

DOI: 10.1097/qai.0000000000002454

Authors: Rima K. Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Aiyappa Parvangada, Hal Martin, Sean Collins, Kirsten L. White

Institution: Gilead Sciences (United States)

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3045364765

FWCI: 0.557

Cites: 39

Cited by: 36

Related to: 10